Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care-Reference-Cited by-同舟云学术

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Published:2018-06-22 Issue:1 Volume:60 Page:49-59
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bell Jill A.¹,Galaznik Aaron¹,Blazer Marlo²,Farrelly Eileen²,Ogbonnaya Augustina²,Raju Aditya²,Eaddy Michael²,Fram Robert J.¹,Faller Douglas V.¹

Affiliation:

1. Millennium Pharmaceuticals, Inc, (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA;

2. Xcenda, LLC, Palm Harbor, Florida, USA

Funder

Takeda Pharmaceutical Company Limited

Takeda

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1464155

Reference27 articles.

1. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes

2. Myelodysplastic syndromes

3. Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology

4. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

5. NCCN.org [Internet]. Fort Washington, PA: NCCN. Myelodysplastic syndromes. V.2.2017; [cited 2017 Apr 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada;Current Oncology;2023-08-30

2. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2;Future Oncology;2023-03

3. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis;Clinical Lymphoma Myeloma and Leukemia;2023-02

4. Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes;Haematologica;2022-12-07

5. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML;Blood Advances;2022-09-02